SCHEDULE: Suvretta Capital Exits Sutro Biopharma Stake

Suvretta Capital Management and its affiliates have reported a complete divestment of their beneficial ownership in Sutro Biopharma, Inc., now holding 0% of the common stock.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an Amendment No. 5 to Schedule 13G for Sutro Biopharma, Inc.
• As of December 31, 2025, the reporting persons collectively beneficially own 0% of Sutro Biopharma, Inc.'s common stock, $0.001 par value.
• This filing indicates a complete divestment of their previously reported stake in the company.
• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development for Sutro Biopharma, Inc. as a significant institutional investor has completely divested its stake, potentially signaling a lack of confidence.

Negatives

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have completely divested their beneficial ownership in Sutro Biopharma, Inc., reducing their stake to 0%.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that a complete exit by a significant institutional investor like Suvretta Capital Management can be a notable event in the biopharma sector, often interpreted by the market as a signal regarding the investor's long-term outlook on the company's prospects or the broader industry segment.

Stakeholder Impact

• Shareholders: May interpret the complete divestment by a significant institutional investor as a negative signal, potentially leading to downward pressure on the stock price.
• Company Management: Could face increased scrutiny regarding investor relations and strategic direction following a major institutional exit.

Key Dates

Recommendation

The complete divestment by Suvretta Capital Management and its affiliates, reducing their beneficial ownership to 0%, represents a significant institutional exit. This action typically signals a lack of confidence in the company's future prospects from this investment group, suggesting existing shareholders consider selling their holdings.

Keywords

Sutro Biopharma, Suvretta Capital Management, Schedule 13G, SEC filing, beneficial ownership, common stock, divestment, institutional investor, Aaron Cowen, Averill Master Fund